IDYA Stock Analysis: Ideaya Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.605m USD | 12M Return: 34.9% | US45166A1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.2M
Qual. Beats: 0
Rev. Trend: 63.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IDEAYA Biosciences (NASDAQ: IDYA) is a US-based precision medicine oncology company that develops targeted therapeutics for patient populations identified through molecular diagnostics. Its lead clinical asset, Darovasertib, is an oral PKC inhibitor being evaluated in uveal melanoma and other ocular cancers across monotherapy and combination settings. The company maintains a broad pipeline spanning antibody-drug conjugates (IDE849, IDE034), PARG inhibitors (IDE161), Pol theta helicase inhibitors (IDE705/GSK101), MAT2A inhibitors (IDE397), PRMT5 inhibitors (IDE892), KAT6/7 inhibitors (IDE574), and WRN helicase inhibitors (IDE275), with several programs in Phase 1 development. IDEAYA also operates proprietary drug discovery platforms, including the DECIPHER dual CRISPR library for synthetic lethality target identification and the INQUIRE chemical library paired with HARMONY machine-learning engines.
The company pursues a partnership-driven business model common among clinical-stage biotechs, with strategic alliances and clinical collaborations with major pharmaceutical players including GlaxoSmithKline, Pfizer, Gilead, Novartis, AstraZeneca, and Roche. These partnerships typically provide milestone payments, R&D funding, and development support while IDEAYA retains certain development and commercialization rights. As a mid-cap biotechnology company within the healthcare sector, IDEAYA is pre-commercial and relies on advancing its pipeline through clinical milestones and partnership economics rather than product revenue.
- Darovasertib Phase 3 data readout in uveal melanoma
- GSK, Pfizer partnership milestones drive revenue
- Cash burn accelerates as pipeline expands into late-stage trials
| Net Income: -175.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 19.85 > 1.0 |
| NWC/Revenue: 333.7% < 20% (prev 9.00k%; Δ -8.67k% < -1%) |
| CFO/TA -0.09 > 3% & CFO -111.7m > Net Income -175.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.1m) vs 12m ago 4.06% < -2% |
| Gross Margin: -34.42% > 18% (prev -2.00k%; Δ 1.96k% > 0.5%) |
| Asset Turnover: 19.92% > 50% (prev 0.67%; Δ 19.25% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.60 (Total Current Assets 864.0m - Total Current Liabilities 82.7m) / Total Assets 1.31b |
| B: -0.72 (Retained Earnings -947.5m / Total Assets 1.31b) |
| C: -0.18 (EBIT TTM -217.0m / Avg Total Assets 1.18b) |
| D: 10.82 (Book Value of Equity 1.20b / Total Liabilities 110.8m) |
| Altman-Z'' = 11.68 = AAA |
| DSRI: 3.0 (Receivables 15.4m/3.00k, Revenue 234.1m/7.00m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.02 (AQ_t 0.32 / AQ_t-1 0.31) |
| SGI: 33.45 (Revenue 234.1m / 7.00m) |
| TATA: -0.05 (NI -175.0m - CFO -111.7m) / TA 1.31b) |
| Beneish M = 21.89 (Cap -4..+1) = D |
As of October 12, 2026, the stock is trading at USD 36.11 with a total of 698,920 shares traded. Over the past week, the price has changed by -3.35%, over one month by -3.94%, over three months by -0.11% and over the past year by +34.89%.
Current recommended Stop Loss: 33.70 (which is 6.7% or 1.6 ATR below the current price).
Ideaya Biosciences has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IDYA.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52.8 | 46.1% |
P/E Forward = 4.649
P/S = 15.397
P/B = 3.014
Revenue TTM = 234.1m USD
EBIT TTM = -217.0m USD
EBITDA TTM = -212.5m USD
Long Term Debt = 28.1m USD (estimated: total debt 29.3m - short term 1.19m)
Short Term Debt = 1.19m USD (from shortTermDebt, last quarter)
Debt = 29.3m USD (from shortLongTermDebtTotal, last quarter) (leases 29.3m already included)
Net Debt = -799.6m USD (calculated: Debt 29.3m - CCE 829.0m)
Enterprise Value = 2.81b USD (3.60b + Debt 29.3m - CCE 829.0m)
Interest Coverage Ratio = unknown (Ebit TTM -217.0m / Interest Expense TTM 0.0)
EV/FCF = -24.63x (Enterprise Value 2.81b / FCF TTM -113.9m)
FCF Yield = -4.06% (FCF TTM -113.9m / Enterprise Value 2.81b)
FCF Margin = -48.64% (FCF TTM -113.9m / Revenue TTM 234.1m)
Net Margin = -74.75% (Net Income TTM -175.0m / Revenue TTM 234.1m)
Gross Margin = -34.42% ((Revenue TTM 234.1m - Cost of Revenue TTM 314.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.14 (Enterprise Value 2.81b / Total Assets 1.31b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 29.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -171.4m (EBIT -217.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.45 (Total Current Assets 864.0m / Total Current Liabilities 82.7m)
Debt / Equity = 0.02 (Debt 29.3m / totalStockholderEquity, last quarter 1.20b)
Debt / EBITDA = 3.76 (negative EBITDA) (Net Debt -799.6m / EBITDA -212.5m)
Debt / FCF = 7.02 (negative FCF - burning cash) (Net Debt -799.6m / FCF TTM -113.9m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.89% (Net Income -175.0m / Total Assets 1.31b)
RoE = -16.47% (Net Income TTM -175.0m / Total Stockholder Equity 1.06b)
RoCE = -19.89% (EBIT -217.0m / Capital Employed (Equity 1.06b + L.T.Debt 28.1m))
RoIC = -14.09% (negative operating profit) (NOPAT -171.4m / Invested Capital 1.22b)
WACC = 8.11% (E(3.60b)/V(3.63b) * Re(8.18%) + D(29.3m)/V(3.63b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.21 | Cagr: 9.47%
[DCF] Fair Price = unknown (Cash Flow -113.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.05 | # QB: 0
Revenue Correlation: 63.53 | Revenue CAGR: 207.8% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.16 | Chg30d=+0.83% | Revisions=-67% | Analysts=12
EPS current Year (2026-12-31): EPS=-4.58 | Chg30d=+0.57% | Revisions=-69% | GrowthEPS=-258.2% | GrowthRev=-81.2%
EPS next Year (2027-12-31): EPS=-4.01 | Chg30d=+2.46% | Revisions=+0% | GrowthEPS=+12.6% | GrowthRev=+191.4%
[Analyst] Revisions Ratio: -70% (up=3, down=24)